{"entity":{"id":"nct01436968","kind":"trial","name":"Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer","aka":[],"tldr":"A phase 3 trial of Aglatimagene besadenovec in prostate cancer, run by Candel Therapeutics, Inc., active and no longer recruiting.","summary":"Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer is a phase 3 interventional study registered as NCT01436968 by Candel Therapeutics, Inc., with 711 participants planned, started 2011-09 and due to reach its primary completion in 2024-08. Interventions recorded: Aglatimagene besadenovec + valacyclovir, Placebo + valacyclovir. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT01436968","url":"https://clinicaltrials.gov/study/NCT01436968"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["aglatimagene-besadenovec"],"companies":["candel-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct01436968-lancet-oncol-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01436968","phase":"3","setting":"A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer","sponsor":"Candel Therapeutics, Inc.","started":"2011-09","enrolled":711,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01436968/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"aglatimagene-besadenovec","kind":"drug","name":"Aglatimagene besadenovec","route":"/drugs/aglatimagene-besadenovec/"}],"company":[{"id":"candel-therapeutics","kind":"company","name":"Candel Therapeutics","route":"/companies/candel-therapeutics/"}],"paper":[{"id":"paper-nct01436968-lancet-oncol-2026","kind":"paper","name":"Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial","route":"/key-papers/paper-nct01436968-lancet-oncol-2026/"}]}}